Trial reportNature communications2024
Effect of high-dose N-acetylcysteine on exacerbations and lung function in patients with mild-to-moderate COPD: a double-blind, parallel group, multicentre randomised clinical trial.
Abstract readRandomized Controlled TrialMulticenter Study
In one paragraph
Trial report in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of mucolytic agents in patients with chronic obstructive pulmonary disease: a systematic review and network meta-analysis.BMC pulmonary medicine · 2026Pooled it
- Identifying patients with mild-to-moderate COPD who require intensified initial treatment to control annualized clinically important deterioration.NPJ primary care respiratory medicine · 2026Trial
- Updates in COPD Management: From Inflammatory Pathways to Targeted Therapies.European journal of clinical investigation · 2026Review
- Plasma metabolomic signatures enable the diagnosis and prognosis of chronic obstructive pulmonary disease.Nature communications · 2026Article
- Effects of Fine Particulate Matter on Systemic Inflammatory Biomarkers in Elderly Patients with Chronic Obstructive Pulmonary Disease Versus the Healthy Elderly: A Pilot Study.International journal of molecular sciences · 2026Article
- Redefining the role of the thiol-based agentRSC medicinal chemistry · 2026Review
- Clinical characteristics and longitudinal prognosis of patients with mild-to-moderate chronic obstructive pulmonary disease progressing from different lung function trajectories.Journal of thoracic disease · 2026Article
- Mucoactive Agents in Muco-Obstructive Lung Diseases: A Critical Reappraisal of Pharmacological Effects and Clinical Outcomes.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Macrophage membrane-biomimetic bimetallic manganese-platinum nanozymes ameliorate intrapulmonary oxidative stress and inflammation in experimental COPD.Journal of nanobiotechnology · 2026Article
- Airway Mucosal Defense: Mucins, Innate Immunity, and Contemporary Mucoactive Strategies.Biomedicines · 2026Review
- Antioxidants as Therapeutic Tools in the Management of COPD: A Systematic Review with Meta-Analysis.Antioxidants (Basel, Switzerland) · 2026Review
- Review
- Efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in patients with tuberculosis-associated chronic obstructive pulmonary disease: study protocol for a randomised controlled trial.Journal of thoracic disease · 2026Article
- Fibroblast-derived exosomes induce macrophage pyroptosis to mediate orthodontic bone remodeling through the mtDNA/NLRP3 axis.Journal of nanobiotechnology · 2026Article
- Review
- Construction and Validation of Active Case-Finding Tool in Community Participants with Chronic Obstructive Pulmonary Disease Using an Interpretable Machine Learning Approach.International journal of chronic obstructive pulmonary disease · 2026Article
- N-acetylcysteine: evidence based consensus document on the therapeutic advantages in respiratory diseases (NECTAR).Frontiers in medicine · 2026Review
- Fabrication of N-acetylcysteine-loaded chitosan-cloaked polyphenol nanoparticles for treatment of pediatric pneumonia and acute lung injury.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Impulse oscillometry-defined airway abnormalities as a treatable trait for mild-to-moderate COPD: a prospective cohort study with 3-year follow-up.ERJ open research · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors.
Yumin Zhou *State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease & National Center for Respiratory Medicine & Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Fan Wu *State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease & National Center for Respiratory Medicine & Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.ORCID 0000-0003-0720-4674
Zhe Shi *Huizhou First Hospital, Huizhou, China.
Jie Cao *Tianjin Medical University General Hospital, Tianjin, China.
Jia Tian *The Second People's Hospital of Hunan Province, Changsha, China.
Weimin Yao *Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Liping Wei *The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Fenglei Li *Liwan Central Hospital of Guangzhou, Guangzhou, China.
Shan Cai *The Second Xiangya Hospital of Central South University, Changsha, China.
Yao Shen *Department of Pulmonary and Critical Care Medicine, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.
Zanfeng Wang *The First Hospital of China Medical University, Shenyang, China.
Huilan Zhang *Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yanfan Chen *The First Hospital of Wenzhou Medical University, Wenzhou, China.
Yingyun Fu *Shenzhen People's Hospital, Shenzhen, China.
Zhiyi He *The First Hospital of Guangxi Medical University, Nanning, China.
Chun Chang *Peking University Third Hospital, Beijing, China.
Yongliang Jiang *Hunan Provincial People's Hospital, Changsha, China.
Shujing Chen *Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Changli Yang *Wengyuan County People's Hospital, Shaoguan, China.
Shuqing Yu *Lianping County People,s Hospital, Lianping County Hospital of Traditional Chinese Medicine, Heyuan, China.
Heshen Tian *State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease & National Center for Respiratory Medicine & Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Qijian ChengRuijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ziwen ZhaoGuangzhou First People's Hospital, Guangzhou, China.
Yinghua YingKey Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Yong ZhouSir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Shengming LiuDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Jinan University, Guangzhou, China.
Zhishan DengState Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease & National Center for Respiratory Medicine & Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Peiyu HuangState Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease & National Center for Respiratory Medicine & Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.ORCID 0000-0003-1394-0360
Yunzhen ZhangHuizhou First Hospital, Huizhou, China.
Xiangwen LuoLianping County People,s Hospital, Lianping County Hospital of Traditional Chinese Medicine, Heyuan, China.
Haiyan ZhaoTianjin Medical University General Hospital, Tianjin, China.
Jianping GuiThe Second People's Hospital of Hunan Province, Changsha, China.
Weiguang LaiDepartment of Respiratory and Critical Care Medicine, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Guoping HuThe Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Cong LiuThe Second Xiangya Hospital of Central South University, Changsha, China.
Ling SuDepartment of Pulmonary and Critical Care Medicine, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.
Zhiguang LiuHunan Provincial People's Hospital, Changsha, China.
Jianhui HuangLianping County People,s Hospital, Lianping County Hospital of Traditional Chinese Medicine, Heyuan, China.
Dongxing ZhaoState Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease & National Center for Respiratory Medicine & Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Nanshan ZhongState Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease & National Center for Respiratory Medicine & Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Pixin RanState Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease & National Center for Respiratory Medicine & Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China. pxran@gzhmu.edu.cn.ORCID 0000-0001-6651-634X
China N-acetylcysteine in Mild-to-moderate COPD Study Group
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evidence for the treatment of patients with mild-to-moderate chronic obstructive pulmonary disease (COPD) is limited. The efficacy of N-acetylcysteine (an antioxidant and mucolytic agent) for patients with mild-to-moderate COPD is uncertain. In this multicentre, randomised, double-blind, placebo-controlled trial, we randomly assigned 968 patients with mild-to-moderate COPD to treatment with N-acetylcysteine (600 mg, twice daily) or matched placebo for two years. Eligible participants were 40-80 years of age and had mild-to-moderate COPD (forced expiratory volume in 1 second [FEV
Indexed as
AcetylcysteineLungPulmonary Disease, Chronic ObstructiveAdultAgedAged, 80 and overBronchodilator AgentsDisease ProgressionDouble-Blind MethodExpectorantsFemaleForced Expiratory VolumeHumansMaleMiddle AgedRespiratory Function TestsAcetylcysteineBronchodilator AgentsExpectorants
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.